NCT04650269View on ClinicalTrials.gov

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Harm ReductionHIV InfectionsDrug Use
Interventions
DRUG

Biktarvy 50Mg-200Mg-25Mg Tablet

Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months

OTHER

HIV care

HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.

Trial Locations (1)

33136

University of Miami, Miami

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Miami

OTHER